Reported about 18 hours ago
On June 25, Sanofi announced that the FDA granted orphan drug designation to Riliprubart, which is aimed at treating antibody-mediated rejection in solid organ transplantation. This designation is crucial for Sanofi as it offers benefits like tax credits and market exclusivity. Riliprubart is currently in clinical trials for various indications, including kidney transplants and chronic inflammatory demyelinating polyneuropathy.
Source: YAHOO